Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Novo Nordisk ( (NVO) ).
Novo Nordisk has received clearance to proceed with its acquisition of three manufacturing sites from Catalent, following Novo Holdings’ acquisition of Catalent, a global contract development and manufacturing organization. The acquisition, expected to be finalized shortly, is anticipated to have a low single-digit negative impact on Novo Nordisk’s operating profit growth and free cash flow due to the $11.7 billion acquisition price. The acquisition will be mainly debt-financed, and Novo Nordisk does not plan to initiate a share buyback program in 2025.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. The company focuses on driving change to combat serious chronic diseases, with a strong emphasis on diabetes. Novo Nordisk employs about 72,000 people across 80 countries and markets its products in around 170 countries. Its shares are listed on Nasdaq Copenhagen and the New York Stock Exchange.
YTD Price Performance: 4.19%
Average Trading Volume: 5,300,031
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $471.5B
For an in-depth examination of NVO stock, go to TipRanks’ Stock Analysis page.
